Picture Swiss Biotech Association LSUS Swiss Biotech Days 2025 Basel 650x100px

Person › Details

John G. Houston (Arvinas Inc. (Nasdaq: ARVN))

Houston, John G. (Arvinas 201709– CEO joined 201701 as President RnD + CSO before over 28 years at BMS)

	Organisation	Arvinas Inc. (Nasdaq: ARVN)
	Group	Arvinas (Group)
	Former/major organisation	Bristol Myers Squibb Co. (BMS) (NYSE: BMY)
	Group	Bristol Myers Squibb (BMS) (Group)
	Product	PROTAC technology (proteolysis targeting chimeric molecules)
	Product 2	drug development

Record changed: 2021-01-02

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for John G. Houston

[1] Bayer AG. (10/1/19). "Press Release: Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio". Monheim, Boston, MA & New Haven, CT....
[2] Arvinas, Inc.. (6/4/19). "Press Release: Bayer and Arvinas to Collaborate on Human PROTAC Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC Applications". New Haven, CT....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]